New treatment available for chronic inflammatory back pain condition

Cimzia (certolizumab pegol) was recently launched in the UK and Ireland for the treatment of adult patients with severe active axial spondyloarthritis comprising severe active ankylosing spondylitis (AS) and severe active axSpA without radiographic evidence of AS. Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that mainly affects the axial skeleton (spine and sacroiliac joints). Patients diagnosed with this condition may exhibit a combination of any of the following signs and symptoms: pain increasing with rest and improving with exercise; painful inflammation of tendons and ligaments, arthritis, sore red eyes (uveitis), IBD. There may be imaging evidence of inflammation on MRI, or damage to the pelvis (sacroiliac